Worth Asset Management LLC Buys New Stake in Abbott Laboratories $ABT

Worth Asset Management LLC bought a new stake in shares of Abbott Laboratories (NYSE:ABT) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 11,148 shares of the healthcare product maker’s stock, valued at approximately $1,102,000.

Several other institutional investors and hedge funds also recently modified their holdings of ABT. J. Stern & Co. LLP increased its holdings in shares of Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Bank of America Corp DE bought a new position in Abbott Laboratories in the 2nd quarter valued at about $1,603,607,000. Legal & General Group Plc acquired a new position in Abbott Laboratories during the 2nd quarter valued at about $1,082,524,000. Flossbach Von Storch SE bought a new stake in shares of Abbott Laboratories during the 2nd quarter worth about $902,938,000. Finally, Jupiter Topco LLC bought a new position in shares of Abbott Laboratories in the second quarter valued at approximately $732,788,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of NYSE:ABT traded up $0.56 on Wednesday, reaching $98.72. 3,080,576 shares of the company traded hands, compared to its average volume of 11,312,622. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The stock has a market capitalization of $170.81 billion, a PE ratio of 31.94, a P/E/G ratio of 1.86 and a beta of 0.59. The company’s 50 day moving average is $106.71 and its 200-day moving average is $98.45. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $135.13.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.6%. Abbott Laboratories’s payout ratio is currently 81.55%.

Analyst Ratings Changes

Several brokerages recently commented on ABT. BTIG Research boosted their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Rothschild & Co Redburn upgraded Abbott Laboratories from a “neutral” rating to a “buy” rating and lifted their price target for the company from $119.00 to $127.00 in a research report on Friday, October 2nd. Piper Sandler reissued an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Wells Fargo & Company raised their target price on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Finally, Barclays began coverage on Abbott Laboratories in a report on Wednesday. They set an “overweight” rating and a $120.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.88.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.